Insurance - Diversified
Compare Stocks
5 / 10Stock Comparison
ACGL vs PRE vs EXAS vs RNR vs NTRA
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Diagnostics & Research
Medical - Diagnostics & Research
Insurance - Reinsurance
Medical - Diagnostics & Research
ACGL vs PRE vs EXAS vs RNR vs NTRA — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Insurance - Diversified | Medical - Diagnostics & Research | Medical - Diagnostics & Research | Insurance - Reinsurance | Medical - Diagnostics & Research |
| Market Cap | $33.67B | $242M | $20.02B | $12.98B | $31.16B |
| Revenue (TTM) | $19.93B | $69M | $3.25B | $11.49B | $2.31B |
| Net Income (TTM) | $4.40B | $-47M | $-208M | $3.09B | $-208M |
| Gross Margin | 37.2% | 47.2% | 69.7% | 44.6% | 64.8% |
| Operating Margin | 25.0% | -62.9% | -6.4% | 35.5% | -13.4% |
| Forward P/E | 10.1x | — | 582.8x | 7.7x | — |
| Total Debt | $2.73B | $2M | $2.52B | $2.33B | $214M |
| Cash & Equiv. | $993M | $32M | $956M | $1.73B | $1.08B |
ACGL vs PRE vs EXAS vs RNR vs NTRA — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Jul 21 | May 26 | Return |
|---|---|---|---|
| Arch Capital Group … (ACGL) | 100 | 242.4 | +142.4% |
| Prenetics Global Li… (PRE) | 100 | 14.1 | -85.9% |
| Exact Sciences Corp… (EXAS) | 100 | 95.9 | -4.1% |
| RenaissanceRe Holdi… (RNR) | 100 | 197.0 | +97.0% |
| Natera, Inc. (NTRA) | 100 | 191.9 | +91.9% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ACGL vs PRE vs EXAS vs RNR vs NTRA
Each card shows where this stock fits in a portfolio — not just who wins on paper.
ACGL is the #2 pick in this set and the best alternative if sleep-well-at-night is your priority.
- Lower volatility, beta 0.02, Low D/E 11.3%, current ratio 1.21x
- Beta 0.02 vs NTRA's 1.26, lower leverage
- 5.9% ROA vs PRE's -23.7%, ROIC 15.4% vs -20.8%
PRE ranks third and is worth considering specifically for growth exposure.
- Rev growth 201.7%, EPS growth -14.0%, 3Y rev CAGR 91.5%
- 201.7% revenue growth vs RNR's 9.4%
- +205.2% vs ACGL's +2.0%
EXAS lags the leaders in this set but could rank higher in a more targeted comparison.
RNR carries the broadest edge in this set and is the clearest fit for income & stability and valuation efficiency.
- Dividend streak 1 yrs, beta -0.03, yield 0.6%
- PEG 0.26 vs ACGL's 0.35
- Beta -0.03, yield 0.6%, current ratio 5.03x
- Better valuation composite
NTRA is the clearest fit if your priority is long-term compounding.
- 20.9% 10Y total return vs ACGL's 324.0%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 201.7% revenue growth vs RNR's 9.4% | |
| Value | Better valuation composite | |
| Quality / Margins | 26.9% margin vs PRE's -67.4% | |
| Stability / Safety | Beta 0.02 vs NTRA's 1.26, lower leverage | |
| Dividends | 0.6% yield, 1-year raise streak, vs ACGL's 0.0%, (3 stocks pay no dividend) | |
| Momentum (1Y) | +205.2% vs ACGL's +2.0% | |
| Efficiency (ROA) | 5.9% ROA vs PRE's -23.7%, ROIC 15.4% vs -20.8% |
ACGL vs PRE vs EXAS vs RNR vs NTRA — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
ACGL vs PRE vs EXAS vs RNR vs NTRA — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
RNR leads in 3 of 6 categories
ACGL leads 1 • NTRA leads 1 • PRE leads 0 • EXAS leads 0 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
RNR leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
ACGL is the larger business by revenue, generating $19.9B annually — 288.7x PRE's $69M. RNR is the more profitable business, keeping 26.9% of every revenue dollar as net income compared to PRE's -67.4%. On growth, PRE holds the edge at +2.0% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $19.9B | $69M | $3.2B | $11.5B | $2.3B |
| EBITDAEarnings before interest/tax | $5.2B | -$54M | -$41M | $4.1B | -$310M |
| Net IncomeAfter-tax profit | $4.4B | -$47M | -$208M | $3.1B | -$208M |
| Free Cash FlowCash after capex | $6.1B | $0 | $357M | $4.2B | $97M |
| Gross MarginGross profit ÷ Revenue | +37.2% | +47.2% | +69.7% | +44.6% | +64.8% |
| Operating MarginEBIT ÷ Revenue | +25.0% | -62.9% | -6.4% | +35.5% | -13.4% |
| Net MarginNet income ÷ Revenue | +22.1% | -67.4% | -6.4% | +26.9% | -9.0% |
| FCF MarginFCF ÷ Revenue | +30.7% | -23.8% | +11.0% | +36.7% | +4.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | +7.3% | +2.0% | +23.1% | -36.4% | +39.8% |
| EPS Growth (YoY)Latest quarter vs prior year | +39.0% | +36.9% | +90.4% | +100.9% | +185.4% |
Valuation Metrics
RNR leads this category, winning 6 of 7 comparable metrics.
Valuation Metrics
At 5.3x trailing earnings, RNR trades at a 35% valuation discount to ACGL's 8.1x P/E. Adjusting for growth (PEG ratio), RNR offers better value at 0.18x vs ACGL's 0.29x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $33.7B | $242M | $20.0B | $13.0B | $31.2B |
| Enterprise ValueMkt cap + debt − cash | $35.4B | $212M | $21.6B | $13.6B | $30.3B |
| Trailing P/EPrice ÷ TTM EPS | 8.13x | -3.82x | -95.37x | 5.31x | -144.62x |
| Forward P/EPrice ÷ next-FY EPS est. | 10.05x | — | 582.83x | 7.66x | — |
| PEG RatioP/E ÷ EPS growth rate | 0.29x | — | — | 0.18x | — |
| EV / EBITDAEnterprise value multiple | 6.85x | — | — | 3.38x | — |
| Price / SalesMarket cap ÷ Revenue | 1.69x | 2.62x | 6.16x | 1.02x | 13.51x |
| Price / BookPrice ÷ Book value/share | 1.47x | 1.28x | 8.24x | 0.70x | 17.55x |
| Price / FCFMarket cap ÷ FCF | 5.50x | — | 56.10x | 3.51x | 285.53x |
Profitability & Efficiency
ACGL leads this category, winning 4 of 9 comparable metrics.
Profitability & Efficiency
ACGL delivers a 19.0% return on equity — every $100 of shareholder capital generates $19 in annual profit, vs $-29 for PRE. PRE carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to EXAS's 1.05x. On the Piotroski fundamental quality scale (0–9), RNR scores 8/9 vs NTRA's 5/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | +19.0% | -28.9% | -8.7% | +16.6% | -15.3% |
| ROA (TTM)Return on assets | +5.9% | -23.7% | -3.5% | +5.7% | -10.6% |
| ROICReturn on invested capital | +15.4% | -20.8% | -3.6% | +16.0% | -36.1% |
| ROCEReturn on capital employed | +11.6% | -21.2% | -4.0% | +10.7% | -18.3% |
| Piotroski ScoreFundamental quality 0–9 | 7 | 5 | 7 | 8 | 5 |
| Debt / EquityFinancial leverage | 0.11x | 0.01x | 1.05x | 0.12x | 0.13x |
| Net DebtTotal debt minus cash | $1.7B | -$30M | $1.6B | $598M | -$862M |
| Cash & Equiv.Liquid assets | $993M | $32M | $956M | $1.7B | $1.1B |
| Total DebtShort + long-term debt | $2.7B | $2M | $2.5B | $2.3B | $214M |
| Interest CoverageEBIT ÷ Interest expense | 34.86x | -199.93x | -5.47x | 33.28x | -25.21x |
Total Returns (Dividends Reinvested)
NTRA leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ACGL five years ago would be worth $24,398 today (with dividends reinvested), compared to $1,393 for PRE. Over the past 12 months, PRE leads with a +205.2% total return vs ACGL's +2.0%. The 3-year compound annual growth rate (CAGR) favors NTRA at 60.6% vs PRE's 7.6% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +0.7% | +0.6% | +3.1% | +10.6% | -3.9% |
| 1-Year ReturnPast 12 months | +2.0% | +205.2% | +96.9% | +21.9% | +37.3% |
| 3-Year ReturnCumulative with dividends | +30.7% | +24.5% | +53.0% | +45.7% | +314.0% |
| 5-Year ReturnCumulative with dividends | +144.0% | -86.1% | +0.4% | +87.1% | +115.9% |
| 10-Year ReturnCumulative with dividends | +324.0% | -86.1% | +1669.1% | +176.9% | +2089.4% |
| CAGR (3Y)Annualised 3-year return | +9.3% | +7.6% | +15.2% | +13.4% | +60.6% |
Risk & Volatility
Evenly matched — EXAS and RNR each lead in 1 of 2 comparable metrics.
Risk & Volatility
RNR is the less volatile stock with a -0.03 beta — it tends to amplify market swings less than NTRA's 1.26 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. EXAS currently trades 99.9% from its 52-week high vs PRE's 67.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.02x | 0.27x | 0.12x | -0.03x | 1.26x |
| 52-Week HighHighest price in past year | $103.39 | $23.63 | $104.98 | $318.20 | $256.36 |
| 52-Week LowLowest price in past year | $82.45 | $5.07 | $38.81 | $231.17 | $131.81 |
| % of 52W HighCurrent price vs 52-week peak | +91.4% | +67.2% | +99.9% | +94.5% | +85.7% |
| RSI (14)Momentum oscillator 0–100 | 46.3 | 37.1 | 76.4 | 46.9 | 57.1 |
| Avg Volume (50D)Average daily shares traded | 1.9M | 186K | 4.2M | 303K | 1.3M |
Analyst Outlook
RNR leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: ACGL as "Buy", PRE as "Buy", EXAS as "Buy", RNR as "Hold", NTRA as "Buy". Consensus price targets imply 126.8% upside for PRE (target: $36) vs -1.6% for EXAS (target: $103). RNR is the only dividend payer here at 0.55% yield — a key consideration for income-focused portfolios.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Hold | Buy |
| Price TargetConsensus 12-month target | $104.00 | $36.00 | $103.18 | $308.33 | $262.50 |
| # AnalystsCovering analysts | 34 | 1 | 41 | 28 | 27 |
| Dividend YieldAnnual dividend ÷ price | +0.0% | — | — | +0.6% | — |
| Dividend StreakConsecutive years of raises | 0 | — | — | 1 | — |
| Dividend / ShareAnnual DPS | $0.02 | — | — | $1.67 | — |
| Buyback YieldShare repurchases ÷ mkt cap | +5.6% | 0.0% | +0.1% | +12.3% | 0.0% |
RNR leads in 3 of 6 categories (Income & Cash Flow, Valuation Metrics). ACGL leads in 1 (Profitability & Efficiency). 1 tied.
ACGL vs PRE vs EXAS vs RNR vs NTRA: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is ACGL or PRE or EXAS or RNR or NTRA a better buy right now?
For growth investors, Prenetics Global Limited (PRE) is the stronger pick with 201.
7% revenue growth year-over-year, versus 9. 4% for RenaissanceRe Holdings Ltd. (RNR). RenaissanceRe Holdings Ltd. (RNR) offers the better valuation at 5. 3x trailing P/E (7. 7x forward), making it the more compelling value choice. Analysts rate Arch Capital Group Ltd. (ACGL) a "Buy" — based on 34 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — ACGL or PRE or EXAS or RNR or NTRA?
On trailing P/E, RenaissanceRe Holdings Ltd.
(RNR) is the cheapest at 5. 3x versus Arch Capital Group Ltd. at 8. 1x. On forward P/E, RenaissanceRe Holdings Ltd. is actually cheaper at 7. 7x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: RenaissanceRe Holdings Ltd. wins at 0. 26x versus Arch Capital Group Ltd. 's 0. 35x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.
03Which is the better long-term investment — ACGL or PRE or EXAS or RNR or NTRA?
Over the past 5 years, Arch Capital Group Ltd.
(ACGL) delivered a total return of +144. 0%, compared to -86. 1% for Prenetics Global Limited (PRE). Over 10 years, the gap is even starker: NTRA returned +20. 9% versus PRE's -86. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — ACGL or PRE or EXAS or RNR or NTRA?
By beta (market sensitivity over 5 years), RenaissanceRe Holdings Ltd.
(RNR) is the lower-risk stock at -0. 03β versus Natera, Inc. 's 1. 26β — meaning NTRA is approximately -4054% more volatile than RNR relative to the S&P 500. On balance sheet safety, Prenetics Global Limited (PRE) carries a lower debt/equity ratio of 1% versus 105% for Exact Sciences Corporation — giving it more financial flexibility in a downturn.
05Which is growing faster — ACGL or PRE or EXAS or RNR or NTRA?
By revenue growth (latest reported year), Prenetics Global Limited (PRE) is pulling ahead at 201.
7% versus 9. 4% for RenaissanceRe Holdings Ltd. (RNR). On earnings-per-share growth, the picture is similar: Exact Sciences Corporation grew EPS 80. 3% year-over-year, compared to -14. 0% for Prenetics Global Limited. Over a 3-year CAGR, PRE leads at 91. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — ACGL or PRE or EXAS or RNR or NTRA?
Arch Capital Group Ltd.
(ACGL) is the more profitable company, earning 22. 1% net margin versus -63. 1% for Prenetics Global Limited — meaning it keeps 22. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: RNR leads at 31. 5% versus -40. 5% for PRE. At the gross margin level — before operating expenses — EXAS leads at 69. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is ACGL or PRE or EXAS or RNR or NTRA more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, RenaissanceRe Holdings Ltd. (RNR) is the more undervalued stock at a PEG of 0. 26x versus Arch Capital Group Ltd. 's 0. 35x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, RenaissanceRe Holdings Ltd. (RNR) trades at 7. 7x forward P/E versus 582. 8x for Exact Sciences Corporation — 575. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PRE: 126. 8% to $36. 00.
08Which pays a better dividend — ACGL or PRE or EXAS or RNR or NTRA?
In this comparison, RNR (0.
6% yield) pays a dividend. ACGL, PRE, EXAS, NTRA do not pay a meaningful dividend and should not be held primarily for income.
09Is ACGL or PRE or EXAS or RNR or NTRA better for a retirement portfolio?
For long-horizon retirement investors, Exact Sciences Corporation (EXAS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
12), +1669% 10Y return). Both have compounded well over 10 years (EXAS: +1669%, NTRA: +20. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between ACGL and PRE and EXAS and RNR and NTRA?
These companies operate in different sectors (ACGL (Financial Services) and PRE (Healthcare) and EXAS (Healthcare) and RNR (Financial Services) and NTRA (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: ACGL is a mid-cap deep-value stock; PRE is a small-cap high-growth stock; EXAS is a mid-cap high-growth stock; RNR is a mid-cap deep-value stock; NTRA is a mid-cap high-growth stock. RNR pays a dividend while ACGL, PRE, EXAS, NTRA do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.